Artivion (NYSE:AORT) Price Target Raised to $58.00 at Needham & Company LLC

Artivion (NYSE:AORT) had its target price upped by analysts at Needham & Company LLC from $50.00 to $58.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 27.15% from the company’s previous close.

A number of other brokerages also recently weighed in on AORT. JMP Securities lifted their price target on Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a report on Friday, October 10th. Canaccord Genuity Group lifted their target price on Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Stifel Nicolaus raised their price target on shares of Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and an average price target of $48.97.

Artivion Trading Down 4.0%

Shares of AORT stock traded down $1.89 during trading hours on Friday, reaching $45.62. 94,594 shares of the stock traded hands, compared to its average volume of 431,618. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $2.15 billion, a PE ratio of -108.61 and a beta of 1.65. Artivion has a 1-year low of $21.97 and a 1-year high of $47.69. The business has a fifty day moving average price of $42.42 and a 200 day moving average price of $35.25.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The business’s quarterly revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Artivion will post 0.37 EPS for the current year.

Insider Activity

In other news, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the completion of the sale, the senior vice president directly owned 64,200 shares of the company’s stock, valued at approximately $2,826,084. This represents a 22.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 23,356 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the sale, the senior vice president directly owned 172,129 shares of the company’s stock, valued at approximately $7,403,268.29. This trade represents a 11.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 74,858 shares of company stock worth $3,250,129. Insiders own 7.60% of the company’s stock.

Institutional Trading of Artivion

A number of institutional investors and hedge funds have recently modified their holdings of the company. MCF Advisors LLC increased its holdings in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after buying an additional 614 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. State of Wyoming bought a new stake in shares of Artivion in the 3rd quarter valued at approximately $80,000. Tower Research Capital LLC TRC raised its holdings in shares of Artivion by 447.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after buying an additional 4,422 shares in the last quarter. Finally, Diversified Trust Co bought a new position in shares of Artivion during the 3rd quarter worth approximately $200,000. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.